Fabtech Technologies Ltd

Director changes

• Re-appointment of Amjad Arbani as Director; effective Aug 24, 2026; retires by rotation.
• Re-appointment of Naushad Panjwani as Non-Executive Independent Director; effective Aug 24, 2026; second five-year term.
• Not debarred and not related to other directors.
• Profile not provided in filing; available on Fabtech's website.

AGM Details

• AGM held on 24 August 2026 at 02:00 p.m. IST via VC/OAVM.
• Deemed venue: Registered Office, Mumbai.
• Quorum met through VC/OAVM.
• Remote e-voting window: 19–23 August 2026.
• Cut-off date for voting eligibility: 17 August 2026.
• AGM concluded at 02:52 p.m. IST.

Key Resolutions

• Ordinary: Adoption of standalone and consolidated financial statements for FY ended 31 March 2026.
• Ordinary: Re-appointment of Amjad Arbani, retiring by rotation.
• Ordinary: Final dividend of Rs 0.60 per equity share.
• Ordinary: Approval of material related party transactions with FTS Cleanrooms Systems LLC.
• Special: Re-appointment of Naushad Panjwani as Non-Executive Independent Director for a second term.

Voting Results

• Voting results awaited; Scrutinizer’s report to be submitted to stock exchanges.
• E-voting remained open post-meeting for 15 minutes to cast votes.

Director Changes

• Amjad Arbani proposed for re-appointment.
• Naushad Panjwani to continue as Non-Executive Independent Director for second term.

Project win

• Fabtech's UAE subsidiary secures AED 9.92 million turnkey project for Aroma King
• Fast-track completion targeted within six months under single-source execution

Scope of work

• Delivery includes modular controlled environments, cold rooms, flooring, HVAC, and electrical works

Strategic context

• Expands Fabtech's global critical infrastructure platform into UAE flavour manufacturing

Financial performance

• Standalone revenue from operations: Rs 26,804.55 Lakhs.
• Consolidated revenue from operations: Rs 41,077.18 Lakhs.
• Standalone total income: Rs 29,114.07 Lakhs; Consolidated: Rs 43,132.95 Lakhs.
• Standalone net profit: Rs 2,425.30 Lakhs; Consolidated: Rs 3,835.80 Lakhs.
• Basic EPS: Standalone Rs 6.33; Consolidated Rs 10.00.
• IPO completed Oct 2025; 1,20,58,555 shares issued.
• Post-IPO paid-up capital: Rs 44.45 Cr.
• IPO net proceeds: Rs 20,752.02 Lakhs; unutilized Rs 17,921.95 Lakhs.
• Order book: over Rs 900 Crores as of 31 Mar 2026.
• Final dividend: Rs 0.60 per share; cash outflow Rs 2.66 Crores.
• Total cash and equivalents: Rs 8,688.16 Lakhs.
• Total assets: Rs 65,370.29 Lakhs; equity: Rs 41,976.93 Lakhs.
• RoNW: 9.14% (vs 26.83% prior).
• IPO financing impact: net cash from financing Rs 18,711.83 Lakhs.

IPO and capital structure

• IPO proceeds used for working capital: Rs 2,747.24 Lakhs.
• General corporate purposes: Rs 125.00 Lakhs.
• Unutilized IPO proceeds: Rs 17,921.95 Lakhs.
• Equity after IPO: 44,450,794 shares; paid-up capital Rs 44.45 Cr.
• Debt-to-equity ratio declined to 0.10x.
• IPO proceeds timing supported liquidity growth.

Geography and markets

• Revenue by geography includes India, Saudi Arabia, UAE, Kenya, Morocco, Iraq, Bangladesh, Algeria, Egypt.
• India: Rs 4,533.07 Lakhs; Saudi Arabia: Rs 8,272.36 Lakhs.
• UAE: Rs 8,299.21 Lakhs; Kenya: Rs 4,342.16 Lakhs.
• Rest of World: Rs 8,596.94 Lakhs; Morocco: Rs 2,200.96 Lakhs.
• Ongoing expansion across GCC, Africa, and Asia.

Order book and wins

• 900+ Crore consolidated order book as of Mar 31, 2026.
• Animal Vaccine project in Saudi Arabia: ~Rs 65.52 Crores.
• Oral Solid Dosage facility in West Africa: ~Rs 63.6 Crores.
• Next-generation Veterinary facility in North Africa: ~Rs 49-52 Crores.
• KP Group collaboration for green infrastructure in life sciences.

Dividends & shareholder matters

• Final dividend of Rs 0.60 per equity share recommended; AGM approval required.
• Record date for dividend: Aug 17, 2026.
• Dividend tax withheld at source per Income Tax Act.

Governance and board changes

• Board as on Mar 31, 2026: 6 directors; 1 Exec, 2 Non-Exec, 3 Independent.
• Aparna Sharma ceased Independent Director (Apr 2, 2026).
• ShyamKhante ceased Independent Director (Jun 25, 2026).
• Bharti Khanna appointed Additional Independent Director (May 25, 2026).
• Board and committees reconstituted for FY2026-27.
• Independent directors declared independence; familiarisation programs run.

Audit, risk & internal controls

• Statutory auditors: Ajmera & Ajmera; Secretarial: Kiran Doshi & Co.; Internal: SHBA & Co.
• Audit opinions: Unmodified; internal controls adequate and effective.
• Vigil mechanism and whistle-blower policy in place; no FY2025-26 complaints.

CSR and sustainability

• CSR spend FY2025-26: Rs 59.21 Lakhs; focus: environment, education, healthcare.
• Two percent average net profit required: Rs 59.21 Lakhs.
• CSR obligation spent: Rs 59.21 Lakhs; minor excess of Rs 0.66 Lakhs carried forward.

Outlook and risks

• Positive outlook on pharma infra and turnkey opportunities.
• Key risks: FX volatility, project delays, receivables, inflation, geopolitical factors.
• Mitigation: geographic diversification, disciplined working capital, strong internal controls.

Subsidiaries and associates

• Wholly owned: FT Institutions Private Limited; Fabtech Technologies LLC (UAE).
• Step-down: Fabtech Lifecare Company (KSA); FTS Cleanrooms Systems LLC (UAE).
• Associates: Mark Maker Engineering Private Limited (33.33%); FABL International Technologies LLP (49%).
• 51% stake in FABL International Technologies LLP ceased in 2025; now associate.

Meeting Details

• Date: July 28, 2026
• Time: 04:00 p.m. IST
• Type/Mode: Earnings conference call; virtual
• Organizer: Fabtech Technologies Limited

Participants

• Key company participant: Executive Director (company representative)

Purpose

• Discuss unaudited quarterly results for quarter and three months ended June 30, 2026

Additional Notes

• Video recording of the earnings call is available on the company website

Issue overview

• IPO of equity shares; proceeds monitored with no revision or undersubscription noted.
• Main objectives: fund working capital, pursue acquisitions, general corporate purposes, and cover issue expenses.

Utilisation of proceeds

• Utilisation is as per offer document; management undertaking and auditor certificates support.
• No material deviations observed; no shareholder approvals required for deviations.
• Funding working capital: utilised in quarter; funds transferred from monitoring account; fully utilized by quarter end.
• Acquisitions: no utilization during the quarter; progress remains nil.
• General Corporate Purposes: salary payments; board approval obtained for allocation; partial utilisation.
• Issue expenses: utilised; minor unutilised balance remain.
• Unutilised proceeds: invested in fixed deposits and bank accounts; funds parked in monitoring and issue accounts.

Governance and compliance

• All required approvals evidenced by management undertaking and statutory auditor certificate; shareholder approvals not applicable.
• Material events: related party transactions with promoter group entities approved by Board/Audit Committee.
• No adverse regulatory actions or pivotal governance concerns reported.

General Corporate Purpose (GCP)

• GCP object: salaries and wages; board resolution approved allocation.
• Utilisation for GCP: portion used in quarter; allocation aligned with offer document.

Director Re-appointment

• Re-appointment of Naushad Alimohmed Panjwani as Non-Executive Independent Director and Chairperson.
• Effective July 30, 2026, for five-year term, subject to shareholder approval.
• Reason: Board approved on Nomination and Remuneration Committee recommendation.
• Profile: Chartered Accountant with 30+ years in governance, real estate, M&A; ex Knight Frank India Senior Executive Director.
• Notable relationships: No relationship with other directors.
• Not debarred by SEBI or any regulator.

Dematerialisation/rematerialisation status

• No dematerialisation/rematerialisation requests were received during the quarter ended 30 June 2026.